Cagrilintide 5mg
Synthetic, long-acting dual amylin and calcitonin receptor agonist under investigation for metabolic regulation and weight reduction.
Mechanism
Long-acting amylin receptor agonist; suppresses appetite and slows gastric emptying.
Dosing
Titration from 0.6 mg up to 2.4 mg once weekly.
Reconstitution
Add 2.0 mL bacteriostatic water → 2.5 mg/mL.
Storage
Lyophilized: −20 °C; reconstituted: refrigerate 2–8 °C.
Mix & measure Cagrilintide 5mg
Pre-filled with this protocol's recommended BAC water and documented starting dose — edit any field to run your own numbers.
Mix & measure Cagrilintide 5mg
Vial strength → BAC water → target dose
Total doses in vial: 8.3
U-100 syringe: 100 units = 1 mL
Reconstitution math only — not dosing advice. U-100 syringe: 100 units = 1 mL. Advanced calculator →
Dosing Chart
| Phase / Day(s) | Dose & Frequency | Volume (U-100 units / mL) |
|---|---|---|
| Initiation (Weeks 1–4) | 0.6 mg once weekly | 24 units (0.24 mL) |
| Step 1 (Weeks 5–8) | 1.2 mg once weekly | 48 units (0.48 mL) |
| Step 2 (Weeks 9–12) | 1.8 mg once weekly | 72 units (0.72 mL) |
| Maintenance (Week 13+) | 2.4 mg once weekly | 96 units (0.96 mL) |
Reconstitution Steps
- 1
Remove the lyophilized 5 mg cagrilintide vial from −20 °C storage and allow it to equilibrate to room temperature for approximately 15 minutes.
- 2
Disinfect the rubber stopper of the peptide vial and the bacteriostatic water vial using sterile alcohol prep swabs.
- 3
Draw precisely 2.0 mL of bacteriostatic water into a sterile mixing syringe.
- 4
Insert the needle at an angle and slowly inject the bacteriostatic water down the inside glass wall of the peptide vial to avoid excessive foaming.
- 5
Gently swirl and roll the vial between the palms until the lyophilized powder is completely dissolved into a clear solution; do not shake.
- 6
Label the vial with the reconstitution date, concentration (2.5 mg/mL), and technician initials, then store upright under refrigeration at 2–8 °C.
Supplies Needed
Peptide Vial
Provides 5 mg of lyophilized cagrilintide research peptide, yielding approximately eight 0.6 mg doses when fully reconstituted.
Insulin Syringes (U-100)
Used for precise measurement and subcutaneous delivery of 24 units per 0.6 mg research dose, requiring approximately 4 to 8 syringes per evaluation cycle.
Bacteriostatic Water
Supplies sterile diluent containing 0.9% benzyl alcohol, requiring exactly 2.0 mL for full vial reconstitution.
Alcohol Swabs
Used to sanitize vial stoppers and work surfaces, requiring approximately 8 to 16 swabs per multi-week protocol.
Why researchers study it
Appetite suppression mechanisms
Metabolic control and weight management
Synergistic co-administration with GLP-1 agonists
Gastric emptying and gut-brain signaling
These describe what is being studied, not proven benefits, approved uses, or promised results.
Overview
Cagrilintide is a lipidated, long-acting synthetic analogue of human amylin engineered for protracted pharmacokinetics through non-covalent albumin binding. Naturally secreted alongside insulin by pancreatic beta cells, amylin modulates postprandial glucose dynamics and signals satiety. Cagrilintide mimics this physiological hormone with high resistance to proteolytic degradation, permitting once-weekly experimental dosing intervals. The peptide functions primarily by binding to both amylin receptor subtypes and calcitonin receptors within homeostatic and hedonic appetite-regulating centers of the brain, notably the area postrema and the hypothalamus. In laboratory models and human trials, this pathway attenuates neuroendocrine drive for caloric intake, delays gastric emptying, and blunts postprandial glucagon secretion without precipitating hypoglycemia. While cagrilintide demonstrates significant monotherapy efficacy across metabolic and obesity studies, substantial scientific interest focuses on its co-administration with glucagon-like peptide-1 (GLP-1) receptor agonists, particularly semaglutide. Investigational fixed-dose formulations, such as CagriSema, target distinct but complementary central satiety circuits to evaluate synergistic therapeutic outcomes across body weight and glycemic control parameters.
References
- 1.Lau DCW et al., The Lancet, 2021 — Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial
- 2.Frias JP et al., The Lancet, 2023 — Efficacy and safety of co-administered once-weekly cagrilintide 2.4 mg with semaglutide 2.4 mg (CagriSema) in people with type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial
- 3.Johnson R et al., Journal of Medicinal Chemistry, 2025 — Structural and mechanistic insights into dual activation of cagrilintide in amylin and calcitonin receptors
- 4.Holst-Schumacher I et al., Cardiology in Review, 2024 — Cagrilintide: A Long-Acting Amylin Analog for the Treatment of Obesity
Supplies Needed
Suggested supplier
Research use only. Listing a supplier is not an endorsement of any protocol on this site, and nothing sold there is approved for human use.